Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

DAWN

Day One Biopharmaceuticals Inc

Sep 06 • 04:00PM ET

14.20

Dollar change -0.30
Percentage change -2.07	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI XBI IWM VXF VB VBR IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	32.58%	Shs Outstand	87.23M	Perf Week	3.88%
Market Cap	1.25B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-1.02%	Shs Float	59.16M	Perf Month	11.64%
Income	-167.48M	PEG	-	EPS next Q	-0.62	Inst Own	73.46%	Short Float	22.94%	Perf Quarter	10.25%
Sales	8.19M	P/S	152.16	EPS this Y	17.67%	Inst Trans	2.04%	Short Ratio	13.79	Perf Half Y	-8.51%
Book/sh	3.50	P/B	4.06	EPS next Y	7.11%	ROA	-39.35%	Short Interest	13.57M	Perf Year	0.42%
Cash/sh	4.12	P/C	3.44	EPS next 5Y	-	ROE	-45.71%	52W Range	9.67 - 18.07	Perf YTD	-2.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-84.59%	ROI	-54.60%	52W High	-21.42%	Beta	-1.51
Dividend TTM	-	Quick Ratio	4.09	Sales past 5Y	0.00%	Gross Margin	87.49%	52W Low	46.85%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	4.09	EPS Y/Y TTM	15.21%	Oper. Margin	-3570.91%	RSI (14)	51.91	Volatility	5.25% 4.33%
Employees	155	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-2044.43%	Recom	1.27	Target Price	36.44
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	91.73%	Payout	-	Rel Volume	0.47	Prev Close	14.50
Sales Surprise	698.21%	EPS Surprise	93.34%	Sales Q/Q	-	Earnings	Jul 30 BMO	Avg Volume	984.01K	Price	14.20
SMA20	2.61%	SMA50	-0.59%	SMA200	-1.62%	Trades		Volume	465,758	Change	-2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy	$11 → $24
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

Aug-27-24 12:49PM	Taylor Fritzs Girlfriend Morgan Riddle Opts for Classic Little Black Dress on Day One of the U.S. Open 2024 (WWD)
Aug-19-24 11:15AM	Jeff Bezos Said 'I Predict One Day Amazon Will Fail' And Claims Large Companies Only Last '30-Plus Years' Guess How Old Amazon Is? (Benzinga)
Aug-14-24 11:46AM	Bank of America Says Buy These 3 Stocks for a Double-Digit Rally (InvestorPlace)
Jul-30-24 01:52PM	DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:40AM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Loading…
07:30AM	Day One Reports Second Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
07:00AM	Day One Announces Oversubscribed $175.0 Million Private Placement (GlobeNewswire)
Jul-25-24 11:53AM	Ipsen outlines $461m for ex-US rights to Day Ones glioma therapy (Pharmaceutical Technology)
12:58AM	Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor (GlobeNewswire)
Jun-27-24 09:51AM	Lupita Nyongo Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at A Quiet Place: Day One Premiere (WWD)
Jun-24-24 04:50PM	Lupita Nyongo Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for A Quiet Place: Day One Photo Call (WWD)
Jun-22-24 04:11AM	Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Jun-19-24 12:14PM	Day One targets the growing ADC market with MabCare acquisition (Pharmaceutical Technology)
10:29AM	Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up (Zacks)
Jun-18-24 08:30AM	Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers (GlobeNewswire) +11.31%
07:46AM	Loading…
Jun-11-24 07:46AM	Exclusive: Day One Ventures closes its third fund at $150 million (Fortune)
May-30-24 08:30AM	Day One Announces Sale of Priority Review Voucher for $108 Million (GlobeNewswire)
May-07-24 09:25AM	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating (MT Newswires)
May-06-24 10:53PM	DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Day One Reports First Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
03:22AM	Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing (MT Newswires)
May-04-24 02:31AM	Insider Sale at Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Apr-23-24 03:56PM	Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor (GlobeNewswire) +8.19%
03:54PM	Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment (MT Newswires)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Feb-26-24 04:30PM	Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress (GlobeNewswire) +11.05%
Jan-31-24 05:12PM	Dwayne 'The Rock' Johnson's net worth: How the new TKO Board Member built his wealth from $7 (TheStreet)
Jan-17-24 08:00AM	Day One Announces Two New Appointments to Board of Directors (GlobeNewswire)
Dec-19-23 08:00AM	Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
10:00AM	Loading…
Nov-27-23 10:00AM	Milei to Send Shock Package to Argentinas Congress on Day One (Bloomberg)
Nov-17-23 07:00AM	Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine (GlobeNewswire)
Nov-14-23 08:00AM	Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) +6.85%
Nov-06-23 05:16PM	Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:30PM	Day One Reports Third Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-30-23 07:27PM	Apples Journal app has arrived heres whats good and bad (TechCrunch) +17.01%
08:00AM	Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Oct-23-23 01:20PM	Hedge Fund and Insider Trading News: Bill Ackman, Nelson Peltz, Dan Loeb, Coltrane Asset Management, Day One Biopharmaceuticals, Inc. (DAWN), Central Securities Corp. (CET), and More (Insider Monkey)
Oct-20-23 10:20AM	Tesla Stock Had a Horrible Day. Heres What Comes Next. (Barrons.com)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-11-23 09:02PM	Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Aug-16-23 08:00AM	Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience (GlobeNewswire)
Aug-10-23 02:28PM	FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc (GuruFocus.com)
Aug-07-23 04:30PM	Day One Reports Second Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +5.66%
Jun-17-23 08:29AM	Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is favoured by institutional owners who hold 54% of the company (Simply Wall St.)
Jun-12-23 08:00AM	Day One Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-08-23 12:38PM	Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More (Zacks) -8.19%
07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
Jun-06-23 10:31PM	Day One Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-05-23 04:06PM	ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips (Investor's Business Daily)
12:30PM	Why Shares of Day One Pharmaceuticals Are Up Monday (Motley Fool)
Jun-04-23 12:45PM	Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
May-30-23 08:00AM	Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference (GlobeNewswire)
May-25-23 08:30PM	CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
05:00PM	Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-01-23 09:00AM	Day One Reports First Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +16.69%
Apr-30-23 09:57AM	We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-26-23 09:31AM	Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +8.18%
Apr-21-23 01:02PM	Leaked: Apple's Secret Health Play Could Push Out Smaller Apps (TheStreet.com) +5.38%
11:44AM	A Daily Journal For iPhone: Apple Weighs Day One-Like Health App For iPhone Users (Benzinga)
Apr-12-23 08:00AM	Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress (GlobeNewswire)
Mar-21-23 05:30AM	Credit Suisse sets up Hong Kong-style hawker stalls to treat investors to dim sum, pineapple buns at what could be its swan song conference (South China Morning Post)
Mar-06-23 04:30PM	Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress (GlobeNewswire) +7.46%
Feb-27-23 08:00AM	Day One to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-15-23 10:24AM	Billionaire Steve Cohen Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
Jan-09-23 08:57AM	Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses (Benzinga)
08:30AM	Day One to submit its glioma drug to the FDA this year (MarketWatch)
Jan-08-23 05:00PM	Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
Jan-03-23 01:04AM	Startups spring from ashes of Big Tech purge (Reuters) -5.90%
01:00AM	REFILE-FOCUS-Startups spring from ashes of Big Tech purge (Reuters)
Dec-20-22 08:00AM	Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 01:02PM	This Pediatric Cancer Company Makes It To Analyst's Conviction List (Benzinga) +7.51%
Dec-05-22 09:05AM	Is This the DAWN of a Rally for Day One Biopharmaceuticals? (TheStreet.com)
Nov-21-22 08:33AM	We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate (Simply Wall St.)
Nov-17-22 07:00AM	Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-11-22 07:00AM	Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting (GlobeNewswire)
Nov-07-22 04:30PM	Day One Reports Third Quarter 2022 Financial Results and Corporate Progress (GlobeNewswire)
Oct-17-22 08:00AM	Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101) (GlobeNewswire) -5.80%
Sep-12-22 08:30AM	Day One Appoints Garry Nicholson as Chairman of the Board of Directors (GlobeNewswire)
Aug-09-22 08:50AM	Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength (Zacks) -6.72%
Aug-04-22 04:30PM	Day One Reports Second Quarter 2022 Financial Results and Corporate Progress (GlobeNewswire) +6.90% +15.60%
Aug-02-22 08:00AM	Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire) +6.63%
Jul-29-22 11:33AM	What Percentage Of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Do Insiders Own? (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet (Zacks) -5.28%
Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform (Zacks)
Jun-23-22 07:26PM	Insiders Are Flashing a Strong Buy Signal for These 2 Stocks (TipRanks) +8.99%
Jun-21-22 08:30AM	Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-15-22 02:45PM	Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade (Investor's Business Daily)
05:41AM	Here's How Day One Biopharmaceuticals Stock Could Keep Climbing (Motley Fool)
Jun-14-22 08:00PM	Day One Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.82%
05:42PM	Day One Stock Is up 139% This Week. How Much Higher Can It Go? (TipRanks)
05:34PM	Peninsula biotech looks to raise $144M after childhood brain cancer data, big stock jump (American City Business Journals)
09:05AM	We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate (Simply Wall St.)
07:30AM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-13-22 04:17PM	Day One Biopharmaceuticals Scores Triple-Digit Gain With Bullish Numbers In Brain Cancer (Investor's Business Daily) +125.98%
07:56AM	Why Day One Biopharma Shares Are Surging Today (Benzinga)
Jun-12-22 05:00PM	Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma (GlobeNewswire)
May-23-22 08:30AM	Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors (GlobeNewswire)

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dubow Adam	GENERAL COUNSEL	Aug 16 '24	Sale	14.00	3,202	44,825	26,928	Aug 19 06:12 PM
York Charles N II	COO, CFO AND SECRETARY	Aug 16 '24	Sale	14.00	2,633	36,860	232,485	Aug 19 06:07 PM
Blackman Samuel C.	HEAD OF R&D	Aug 16 '24	Sale	14.00	2,232	31,246	1,127,535	Aug 19 05:59 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Aug 16 '24	Sale	14.00	10,681	149,524	98,932	Aug 19 05:53 PM
JEREMY BENDER	Officer	Aug 16 '24	Proposed Sale	14.00	10,681	149,524		Aug 16 05:23 PM
SAMUEL BLACKMAN	Officer	Aug 16 '24	Proposed Sale	14.00	2,232	31,246		Aug 16 05:17 PM
Blackman Samuel C.	HEAD OF R&D	Jul 16 '24	Sale	16.01	20,000	320,226	1,121,081	Jul 17 04:53 PM
Ramasastry Saira	Director	Jun 21 '24	Sale	13.19	10,000	131,877	40,485	Jun 21 07:17 PM
Blackman Samuel C.	HEAD OF R&D	Jun 10 '24	Sale	12.62	30,000	378,588	1,141,081	Jun 12 04:29 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '24	Sale	16.08	7,873	126,588	654,728	May 17 06:27 PM
Blackman Samuel C.	HEAD OF R&D	May 16 '24	Sale	16.08	2,267	36,450	1,171,081	May 17 06:18 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '24	Sale	16.08	2,675	43,011	224,868	May 17 06:15 PM
Dubow Adam	GENERAL COUNSEL	May 16 '24	Sale	16.08	3,253	52,304	21,731	May 17 06:11 PM
Blackman Samuel C.	HEAD OF R&D	May 10 '24	Sale	16.37	10,000	163,743	1,164,662	May 14 06:13 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	17.88	70,051	1,252,183	651,762	May 03 06:48 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 03 '24	Sale	17.85	9,154	163,417	642,602	May 03 06:48 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 02 '24	Sale	17.94	6	108	651,756	May 03 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 01 '24	Sale	17.89	52,183	933,397	225,571	May 03 06:44 PM
York Charles N II	COO, CFO AND SECRETARY	May 03 '24	Sale	17.85	8,078	144,214	217,293	May 03 06:44 PM
York Charles N II	COO, CFO AND SECRETARY	May 02 '24	Sale	17.90	200	3,579	225,371	May 03 06:44 PM
Blackman Samuel C.	HEAD OF R&D	Apr 18 '24	Sale	16.02	10,000	160,163	1,174,662	Apr 22 06:36 PM
Blackman Samuel C.	HEAD OF R&D	Mar 25 '24	Sale	16.01	10,000	160,055	1,184,662	Mar 26 06:09 PM
Blackman Samuel C.	HEAD OF R&D	Mar 11 '24	Sale	15.24	30,000	457,314	1,194,662	Mar 13 04:24 PM
Blackman Samuel C.	HEAD OF R&D	Feb 27 '24	Sale	16.11	20,000	322,166	1,224,662	Feb 28 07:55 PM
Dubow Adam	GENERAL COUNSEL	Feb 16 '24	Sale	15.25	3,242	49,434	16,585	Feb 20 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	Feb 16 '24	Sale	15.25	2,666	40,651	277,754	Feb 20 06:36 PM
Blackman Samuel C.	HEAD OF RESEARCH AND DEVELOPME	Feb 16 '24	Sale	15.25	2,258	34,430	1,244,662	Feb 20 06:26 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.25	7,615	116,114	721,813	Feb 20 06:14 PM
York Charles N II	COO, CFO and Secretary	Nov 16 '23	Sale	11.69	956	11,176	270,170	Nov 17 06:33 PM
Dubow Adam	General Counsel	Nov 16 '23	Sale	11.69	5,313	62,109	11,428	Nov 17 06:30 PM
Blackman Samuel C.	Head of Research and Developme	Nov 16 '23	Sale	11.69	709	8,288	1,238,234	Nov 17 06:26 PM
Bender Jeremy	Chief Executive Officer	Nov 16 '23	Sale	11.69	3,107	36,321	709,429	Nov 17 06:20 PM
AI Day1 LLC	10% Owner	Oct 18 '23	Buy	10.21	979,667	10,000,049	12,433,535	Oct 20 04:02 PM
AI Day1 LLC	10% Owner	Oct 19 '23	Buy	10.06	384,400	3,867,372	12,817,935	Oct 20 04:02 PM
AI Day1 LLC	10% Owner	Oct 20 '23	Buy	9.97	111,387	1,110,907	12,929,322	Oct 20 04:02 PM

Open in Screener

VIR

Vir Biotechnology Inc

Sep 06 • 04:00PM ET

7.76

Dollar change +0.11
Percentage change 1.44	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

VIR Vir Biotechnology Inc daily Stock Chart

Held by: IJR VTI VB IWM VBK VXF XBI IJS IWN SPSM

Index	RUT	P/E	-	EPS (ttm)	-3.58	Insider Own	35.64%	Shs Outstand	134.78M	Perf Week	-6.51%
Market Cap	1.06B	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-0.18%	Shs Float	87.95M	Perf Month	-6.62%
Income	-483.04M	PEG	-	EPS next Q	-1.05	Inst Own	51.03%	Short Float	6.40%	Perf Quarter	-35.23%
Sales	78.88M	P/S	13.44	EPS this Y	26.24%	Inst Trans	-5.27%	Short Ratio	5.47	Perf Half Y	-31.08%
Book/sh	10.50	P/B	0.74	EPS next Y	-11.34%	ROA	-24.69%	Short Interest	5.63M	Perf Year	-35.71%
Cash/sh	8.53	P/C	0.91	EPS next 5Y	7.00%	ROE	-29.78%	52W Range	7.52 - 13.09	Perf YTD	-22.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-34.12%	ROI	-31.60%	52W High	-40.72%	Beta	0.48
Dividend TTM	-	Quick Ratio	12.51	Sales past 5Y	421.39%	Gross Margin	73.88%	52W Low	3.19%	ATR (14)	0.38
Dividend Ex-Date	Nov 03, 2010	Current Ratio	12.51	EPS Y/Y TTM	-83.41%	Oper. Margin	-648.66%	RSI (14)	34.52	Volatility	3.93% 4.03%
Employees	587	Debt/Eq	0.08	Sales Y/Y TTM	-83.93%	Profit Margin	-612.40%	Recom	1.78	Target Price	31.25
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	30.09%	Payout	-	Rel Volume	0.72	Prev Close	7.65
Sales Surprise	-59.14%	EPS Surprise	-13.97%	Sales Q/Q	-19.02%	Earnings	Aug 01 AMC	Avg Volume	1.03M	Price	7.76
SMA20	-7.70%	SMA50	-14.04%	SMA200	-19.71%	Trades		Volume	742,002	Change	1.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight	$26
Mar-13-20	Downgrade	Goldman	Buy → Neutral

Show Previous Ratings

Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Loading…
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
08:05AM	Loading…
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%
May-21-24 08:17AM	Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 (Business Wire) +5.37%
May-13-24 07:21PM	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies (PR Newswire)
May-09-24 10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 09:55AM	Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet (Zacks)
May-03-24 01:05PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript (Insider Monkey) +13.18%
06:05AM	Q1 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 09:56PM	VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 (InvestorPlace) +5.03%
06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 04:05PM	Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 (Business Wire)
Apr-24-24 12:00PM	What Makes Vir Biotechnology (VIR) a New Buy Stock (Zacks)
Apr-18-24 08:00AM	Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (Business Wire)
Apr-11-24 04:30PM	Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
07:01PM	Loading…
Apr-04-24 07:01PM	Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares (GuruFocus.com)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Mar-19-24 02:58PM	From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires (InvestorPlace) -6.37%
Mar-13-24 11:07AM	Billionaires Biotech Bets: 3 Stocks Dominating Bill Gates Portfolio (InvestorPlace)
Mar-05-24 08:05AM	Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule (Business Wire)
Feb-23-24 01:54PM	Q4 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +11.94%
10:34AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade (Zacks)
08:05AM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-22-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:30PM	Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer (Business Wire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.62%
Feb-01-24 04:05PM	Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 (Business Wire)
Jan-15-24 11:32AM	Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why (Zacks)
Dec-17-23 07:00AM	I See a Vir-y Good Trade (TheStreet.com)
07:00AM	I See a Good Trade on a $10 Biotech Stock (TheStreet.com)
Dec-13-23 04:05PM	Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation (Business Wire) +9.11%
Dec-06-23 04:05PM	Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference (Business Wire)
Nov-30-23 06:10AM	7 Small-Cap Stocks to Buy BEFORE the Year-End Rally (InvestorPlace)
Nov-13-23 08:00AM	Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLDs The Liver Meeting 2023 (Business Wire)
Nov-10-23 08:00AM	Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLDs The Liver Meeting 2023 (Business Wire) +7.99%
Nov-08-23 08:05AM	Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (Business Wire)
Nov-04-23 11:42AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 09:02AM	Q3 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM	Vir Biotechnology Inc (VIR) Reports Q3 2023 Financial Results (GuruFocus.com) +5.13%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-12-23 04:05PM	Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference (GlobeNewswire) -5.98%
Oct-11-23 08:00AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Oct-05-23 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-03-23 07:59AM	Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats (GlobeNewswire)
Sep-20-23 08:00AM	Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV (GlobeNewswire)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Sep-08-23 09:34AM	Adobe upgraded, DigitalOcean double downgraded: Wall Street's top analyst calls (The Fly)
Aug-29-23 04:30PM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 10:15AM	Is Vir Biotechnology Stock a Buy? (Motley Fool)
Aug-07-23 06:03AM	Analysts Just Made A Major Revision To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Forecasts (Simply Wall St.)
Aug-04-23 01:40PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
Jul-21-23 10:11AM	Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues (Zacks) +12.99%
Jul-20-23 04:50PM	Vir's flu-prevention drug fails mid-stage clinical trial, stock dips (American City Business Journals) -44.90%
11:31AM	Why Shares of Vir Biotechnology Are Plunging Thursday (Motley Fool)
08:00AM	Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness (GlobeNewswire)
Jun-29-23 09:00AM	Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer (GlobeNewswire)
Jun-25-23 08:00AM	Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL Congress 2023 (PR Newswire)
Jun-24-23 05:30AM	Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D (GlobeNewswire)
Jun-21-23 08:00PM	VIR: Lowering target price to $26.00 (Argus Research)
Jun-07-23 02:13AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL Congress 2023 (GlobeNewswire)
Jun-05-23 04:05PM	Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-17-23 04:05PM	Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders (GlobeNewswire)
May-16-23 09:25AM	Billionaire Steve Cohen Snaps Up These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks)
May-15-23 08:35AM	Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 50% of the company (Simply Wall St.)
08:00AM	Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer (GlobeNewswire)
May-11-23 08:30AM	Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFN and an NRTI (GlobeNewswire)
May-10-23 02:07PM	7 Top-Rated Stocks That Will Boost Your Portfolio in 2023 (InvestorPlace)
May-04-23 07:45PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	The 7 Best Bargain Stocks to Buy for May 2023 (InvestorPlace)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 04:05PM	Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference (GlobeNewswire)
May-02-23 09:00AM	Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention (GlobeNewswire)
Apr-28-23 10:00AM	Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-27-23 10:03AM	Earnings Preview: Vir Biotechnology, Inc. (VIR) Q1 Earnings Expected to Decline (Zacks)
Apr-26-23 08:00PM	VIR: What does Argus have to say about VIR? (Argus Research)
Apr-11-23 04:05PM	Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-05-23 01:40PM	7 Thrilling Biotech Stocks for Aggressive Investors to Buy (InvestorPlace)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ramasastry Saira	Director	Jun 11 '24	Sale	10.95	4,000	43,789	14,619	Jun 12 12:21 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '24	Sale	9.46	72,995	690,365	678,457	Apr 04 04:14 PM
HANLY ANN M.	EVP & Chief Technology Officer	Apr 01 '24	Sale	10.05	2,711	27,251	132,069	Apr 02 08:58 PM
Lee Sung	EVP & Chief Financial Officer	Mar 27 '24	Sale	9.89	6,008	59,404	100,492	Mar 28 12:18 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 22 '24	Sale	10.05	12,296	123,521	134,780	Feb 26 07:34 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 22 '24	Sale	10.05	14,568	146,344	250,111	Feb 26 07:31 PM
SCANGOS GEORGE A	Director	Feb 26 '24	Sale	11.65	17,722	206,522	112,989	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 22 '24	Sale	10.05	10,028	100,737	130,711	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 20 '24	Sale	10.22	16,872	172,385	140,739	Feb 20 09:02 PM
SCANGOS GEORGE A	Director	Feb 16 '24	Sale	10.24	10,878	111,386	157,611	Feb 20 09:02 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 16 '24	Sale	10.24	3,321	34,006	264,679	Feb 16 06:56 PM
Pang Phillip	EVP & Chief Medical Officer	Jan 02 '24	Option Exercise	1.38	80,000	110,299	268,000	Jan 03 02:47 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Sep 06 • 04:00PM ET

41.12

Dollar change -0.53
Percentage change -1.27	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.34	Insider Own	20.68%	Shs Outstand	46.72M	Perf Week	-2.05%
Market Cap	1.96B	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-0.45%	Shs Float	37.84M	Perf Month	5.54%
Income	-106.65M	PEG	-	EPS next Q	-0.43	Inst Own	95.92%	Short Float	18.16%	Perf Quarter	64.74%
Sales	264.38M	P/S	7.42	EPS this Y	55.09%	Inst Trans	11.22%	Short Ratio	9.19	Perf Half Y	45.76%
Book/sh	4.81	P/B	8.54	EPS next Y	54.33%	ROA	-19.32%	Short Interest	6.87M	Perf Year	44.23%
Cash/sh	5.83	P/C	7.05	EPS next 5Y	-	ROE	-69.35%	52W Range	23.14 - 45.23	Perf YTD	39.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.57%	ROI	-19.59%	52W High	-9.09%	Beta	1.16
Dividend TTM	-	Quick Ratio	3.09	Sales past 5Y	88.90%	Gross Margin	73.04%	52W Low	77.70%	ATR (14)	1.90
Dividend Ex-Date	-	Current Ratio	3.28	EPS Y/Y TTM	50.67%	Oper. Margin	-40.07%	RSI (14)	50.25	Volatility	4.27% 4.77%
Employees	264	Debt/Eq	1.38	Sales Y/Y TTM	128.34%	Profit Margin	-40.34%	Recom	1.09	Target Price	59.27
Option/Short	Yes / Yes	LT Debt/Eq	1.38	EPS Q/Q	73.15%	Payout	-	Rel Volume	0.29	Prev Close	41.65
Sales Surprise	3.79%	EPS Surprise	-10.10%	Sales Q/Q	107.68%	Earnings	Aug 07 AMC	Avg Volume	747.71K	Price	41.12
SMA20	-1.70%	SMA50	4.12%	SMA200	34.25%	Trades		Volume	218,908	Change	-1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
11:01AM	Loading…
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Loading…
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-24 08:00AM	Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies (Business Wire) +27.31%
Jun-16-24 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 (Business Wire)
Jun-10-24 10:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report? (Zacks)
Jun-06-24 09:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress (Business Wire) -5.10%
Jun-05-24 04:05PM	Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-03-24 06:46AM	EMA CHMP endorses Mirum Pharmaceuticals LIVMARLI for PFIC (Pharmaceutical Technology) +5.49%
May-31-24 08:30AM	Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older (Business Wire)
May-29-24 08:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress (Business Wire)
10:02AM	Loading…
May-28-24 10:02AM	Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns (Zacks)
May-18-24 07:00AM	Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting (Business Wire)
May-13-24 09:40AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:55PM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss (GuruFocus.com)
01:12PM	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating (MT Newswires)
May-09-24 11:46AM	Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
07:40AM	Q1 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:49AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ... (GuruFocus.com)
May-08-24 04:02PM	Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:10PM	Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:30AM	Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC (Business Wire)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
May-01-24 04:10PM	Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 (Business Wire)
Apr-25-24 10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-10-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 08:30AM	Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canadas CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome (Business Wire)
Mar-29-24 11:30AM	Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-25-24 11:46PM	Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares (GuruFocus.com)
07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Mar-15-24 09:32AM	Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use (Zacks)
Mar-13-24 06:00PM	Mirum Pharmaceuticals LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (Business Wire)
Mar-08-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-29-24 11:34AM	Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat (Zacks)
09:49AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:30AM	Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirums LIVMARLI (Business Wire)
Feb-28-24 05:35PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:38PM	Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ... (GuruFocus.com)
04:03PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Feb-21-24 04:05PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 (Business Wire)
Feb-09-24 09:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.97%
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-23-24 11:44AM	Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback (Zacks)
Jan-19-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-16-24 08:30AM	Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer (Business Wire)
Jan-15-24 04:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.91%
Jan-08-24 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates (Business Wire)
Jan-03-24 08:45AM	Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 01:05PM	United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023 (Associated Press Finance) -15.87%
08:37AM	Mirum Pharma's liver disease therapy fails in mid-stage study (Reuters)
08:30AM	Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia (Business Wire)
Dec-08-23 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-20-23 04:05PM	Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 02:00PM	Mirum Pharmaceuticals Presents New Data at The Liver Meeting (Business Wire) +6.57%
Nov-10-23 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-23 09:10AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference (Business Wire) +5.67%
Nov-02-23 07:13PM	Mirum Pharmaceuticals Inc (MIRM) Reports Q3 2023 Revenue of $47.7 Million, Up 154% YoY (GuruFocus.com)
04:05PM	Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-30-23 10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Mirum Pharmaceuticals to Present New Data at The Liver Meeting (Business Wire)
Oct-27-23 08:45AM	Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (Business Wire)
Oct-17-23 04:30PM	Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (Business Wire)
Oct-11-23 04:52PM	7 Small-Cap Stocks That Get the Nod from Wall Street (InvestorPlace) -5.79%
Oct-10-23 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-23 05:00PM	Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN (Business Wire)
Oct-02-23 08:30AM	Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis (Business Wire) -7.28%
Sep-26-23 08:30AM	Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Sep-21-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire)
Sep-15-23 03:05PM	Director Michael Grey Sells 14,608 Shares of Mirum Pharmaceuticals Inc (MIRM) (GuruFocus.com)
08:30AM	Mirum Pharmaceuticals Merits a Healthy Endorsement Based on Its Charts (TheStreet.com)
06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Sep-14-23 01:15PM	Director Patrick Heron Buys 8,437 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com) +8.01%
Sep-13-23 01:01PM	Insider Buying: CFO Eric Bjerkholt Acquires 10,000 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 10:07AM	Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer (Business Wire)
Sep-08-23 11:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.94	34,013	99,862	126,783	Jul 24 05:32 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '24	Sale	34.00	375	12,750	2,426	Jul 03 06:19 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Option Exercise	2.94	30,559	89,721	57,965	Jun 25 05:15 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Sale	34.00	30,559	1,039,006	27,406	Jun 25 05:15 PM
Ramasastry Saira	Director	Jun 05 '24	Option Exercise	14.12	5,000	70,600	5,000	Jun 07 06:20 PM
Ramasastry Saira	Director	Jun 05 '24	Sale	25.68	5,000	128,400	0	Jun 07 06:20 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 27 '24	Buy	24.80	2,000	49,600	14,000	Mar 27 08:47 PM
Radovich Peter	PRESIDENT AND COO	Mar 25 '24	Sale	25.80	4,303	111,017	29,013	Mar 25 05:41 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 18 '24	Buy	25.80	2,000	51,600	12,000	Mar 18 05:34 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Feb 02 '24	Sale	26.19	1,214	31,797	28,691	Feb 05 09:12 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Feb 02 '24	Sale	26.19	847	22,184	104,407	Feb 05 09:10 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '24	Sale	26.19	1,790	46,883	34,695	Feb 05 09:05 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '24	Sale	26.19	6,013	157,491	104,112	Feb 05 09:04 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '24	Sale	26.19	735	19,251	1,759	Feb 02 09:28 PM
Radovich Peter	CHIEF OPERATING OFFICER	Jan 08 '24	Sale	28.03	1,408	39,473	36,485	Jan 09 08:28 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Jan 08 '24	Sale	28.04	1,019	28,568	105,254	Jan 09 08:25 PM
Vig Pamela	HEAD OF RESEARCH & DEVELOPMENT	Jan 08 '24	Sale	28.03	1,408	39,472	29,905	Jan 09 08:21 PM
Peetz Christopher	PRESIDENT AND CEO	Jan 08 '24	Sale	28.03	5,209	146,033	110,125	Jan 09 08:12 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 08 '24	Sale	28.04	528	14,803	722	Jan 09 08:09 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Option Exercise	2.94	2,500	7,350	2,500	Dec 06 05:16 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Sale	32.40	2,500	81,000	0	Dec 06 05:16 PM
Heron Patrick J	Director	Sep 13 '23	Buy	31.02	2,625	81,425	159,053	Sep 15 04:56 PM
GREY MICHAEL G	Director	Sep 14 '23	Option Exercise	2.94	14,216	41,738	14,216	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 13 '23	Option Exercise	2.94	392	1,151	392	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 14 '23	Sale	32.00	14,216	454,912	0	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 13 '23	Sale	32.00	392	12,544	0	Sep 14 07:33 PM
Heron Patrick J	Director	Sep 11 '23	Buy	30.30	4,687	142,027	152,678	Sep 13 04:39 PM
Heron Patrick J	Director	Sep 12 '23	Buy	30.60	3,750	114,764	156,428	Sep 13 04:39 PM
BJERKHOLT ERIC	Chief Financial Officer	Sep 11 '23	Buy	29.65	10,000	296,492	10,000	Sep 12 06:23 PM

DAWN

Day One Biopharmaceuticals Inc

VIR

Vir Biotechnology Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience